Combined scleral buckle and BGI is effective

Article

Combined scleral buckle and Baerveldt glaucoma implantation (BGI) is effective for managing coexisting glaucoma and retinal detachment.

Combined scleral buckle and Baerveldt glaucoma implantation (BGI) is effective for managing coexisting glaucoma and retinal detachment, while minimizing surgical risk, states a journal paper.

Professor V.C. Lima et al., Department of Ophthalmology and Einhorn Clinical Research Center, The New York Eye and Ear Infirmary, New York, USA, included 30 eyes of 30 patients in a retrospective, consecutive, noncomparative, interventional case series.

All patients underwent simultaneous scleral and BGI surgery and were separated into a staged BGI group of 21 patients and a non-staged BGI group consisting of 9 patients. Successful IOP control was identified as 6 mmHg ≤ IOP ≤ 18 mmHg.

Mean best-corrected visual acuity improved from 2.0 preoperatively to 1.7 postoperatively. In the staged group 62% required second-stage tube insertion postoperatively. Mean IOP was reduced from 31.1±10.8 to 12.7±6.0 mmHg, mean number of glaucoma medications was lowered from 2.9±1.4 to 1.2±1.3.

Combined scleral buckle and BGI is a successful management technique for coexisting glaucoma and retinal detachment and greatly reduces surgical risk.

Please visit the Journal of Glaucoma for more information.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.